drugset / Trial / NCT00605059
Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I AV94, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and Alzheimer's (AD) subjects To perform blood metabolite characterization of 123-I AV94 in healthy and AD subjects to determine the metabolic fate and nature of metabolites in assessment of 123-I AV94 as a single photon computed tomography (SPECT) brain imaging agent Evaluate the test/retest reproducibility of 123-I AV94 and SPECT in AD subjects and healthy controls
Timeline
- Start
- 2007-08
- Primary completion
- 2008-06
- Completion
- 2008-06
Outcome
Outcome not reported
Stopped: “Scans showed no visual difference between affected subjects \& healthy volunteers”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 123-I AV94 | Diagnostic / imaging agent | — | — |